Market Overview

Recap: Ra Medical Systems Q2 Earnings


Shares of Ra Medical Systems (NYSE:RMED) decreased 9.56% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 62.93% year over year to ($0.43), which missed the estimate of ($0.22).

Revenue of $900,000 decreased by 58.20% from the same period last year, which beat the estimate of $550,000.

Looking Ahead

Ra Medical Systems hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Aug 11, 2020

Time: 04:30 PM

ET Webcast URL:

Recent Stock Performance

Company's 52-week high was at $2.93

52-week low: $0.28

Price action over last quarter: down 61.36%

Company Description

Ra Medical Systems Inc is a commercial-stage medical device company leveraging its laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases. Its products restore blood-flow in arteries and clearing chronic skin conditions. The company's products include DABRA and Pharos. DABRA System is used as a tool in the treatment of peripheral artery disease, or PAD, a form of peripheral vascular disease, which commonly occurs in the legs. Pharos is designed for use in the treatment of inflammatory skin conditions and as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma. It operates in two segments namely the vascular segment and the dermatology segment.


Related Articles (RMED)

View Comments and Join the Discussion!

Posted-In: Earnings